Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 3/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.30 |
| ▸ | CDK2 | P24941 | 3/20 | 0.30 |
| ▸ | CDK3 | Q00526 | 3/20 | 0.30 |
| ▸ | CDK1 | P06493 | 2/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | GRK2 | P25098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20858102 | 0.71 | HCAR2 (0.32) | IDO1TRPA1 | |
| SCHEMBL22967682 | 0.69 | AKR1B1 (0.37) | TRPV1NR3C1 | |
| SCHEMBL21938210 | 0.69 | IDO1 (0.38) | IDO1METAP2TRPA1AXLCDK2 | |
| SCHEMBL24854231 | 0.68 | — | — | |
| SCHEMBL21024009 | 0.66 | AXL (0.34) | TRPV1TRPA1AXL | |
| SCHEMBL24285781 | 0.65 | IDO1 (0.34) | TRPV1IDO1METAP2TRPA1AXL | |
| SCHEMBL17030759 | 0.65 | IDO1 (0.41) | IDO1METAP2TRPA1AXLCDK2 | |
| SCHEMBL24854355 | 0.64 | JAK2 (0.31) | CDK2 | |
| SCHEMBL21733602 | 0.64 | NOS1 (0.31) | — | |
| SCHEMBL18456308 | 0.64 | AXL (0.50) | TRPV1IDO1METAP2TRPA1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | TRPV1 4748/4885C5AR1 1271/4885IDO1 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.